Novo Jumps Most in Month as Ozempic Beats Older Lilly Drug (1)

Novo Nordisk A/S rose the most in a month after its diabetes blockbuster Ozempic beat Eli Lilly & Co.’s older drug Trulicity in a real-world survey of certain US patients.

Medicare patients who took Ozempic were 23% less likely to have a heart attack, stroke or die than people on Trulicity, Novo said in a presentation at the European Association for the Study of Diabetes conference in Vienna. The study followed almost 60,000 people with diabetes and heart disease.

Read More: Lilly’s GLP-1 Pill Tops Older Novo Drug in Diabetes Trial

Both Ozempic and Trulicity are in the class ...